Hutch News

Hutch News

Stories tagged 'Colleen Delaney'

How research and industry partnerships can advance cancer care

Fred Hutch, Merck co-host inaugural ‘Oncology Summit’ to capture non-profit and for-profit outlooks on cancer care

Sept. 27, 2016 | By Rachel Tompa / Fred Hutch News Service

Inaugural 'Oncology Summit,' co-hosted by Fred Hutch and Merck, allowed investors, key players in life sciences to collaborate and share scientific stories.

View story >


For high-risk leukemia patients, umbilical cord blood transplant associated with lower risk of relapse

Study compares ‘alternative’ donor source vs. traditional transplantation of blood stem cells from an adult, unrelated donor

Sept. 7, 2016 | By Rachel Tompa / Fred Hutch News Service

A new study by Fred Hutch researchers, published today in The New England Journal of Medicine, has found that umbilical cord blood transplants may have advantages beyond being an alternative source of stem cells for patients without a traditional donor match. They also are associated with a lower risk of relapse in high-risk leukemia patients.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

July 8, 2016

Dr. Colleen Delaney leads first test of "off-the-shelf" cord blood cell product outside the transplant setting; Dr. Justin Taylor receives Hartwell Foundation award to research alternative to RSV vaccine

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

March 3, 2016

Drs. Colleen Delaney, Harlan Robins named 2016 Leaders in Health Care; Hutch study finds CMV viral load can act as surrogate endpoint for clinical trials; A new target for Tumor Paint: BLZ-100 lights up head and neck cancers; Dr. Stephen Tapscott appointed to NIAMS advisory council

View story >


I'm here because ...

Fred Hutch researchers share what motivates them

Dec. 28, 2015 | By Fred Hutch staff

Eliminating cancer and related diseases is more than an idea — it’s what keeps our researchers motivated every day. Fred Hutch scientists share what keeps them going.

View story >


‘I want this to be something everyone can get’

New Fred Hutch spinoff to commercialize cord blood stem cell therapies based on work by Drs. Colleen Delaney, Irwin Bernstein

Dec. 3, 2015 | By Susan Keown / Fred Hutch News Service

A new Fred Hutch spinoff, Nohla Therapeutics, will commercialize cord blood stem cell therapies based on work by Dr. Colleen Delaney and Dr. Irwin Bernstein. In preliminary studies, the company’s first product helps stem cells engraft more quickly after transplant and protects patients from deadly infections during this vulnerable period.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.